De-Escalated Neoadjuvant Regimen Effective in HR-Positive/HER2-Positive Early Breast Cancer

Summary: Good news for women with early-stage breast cancer! A new study shows that a "de-escalated" or lighter treatment plan is highly effective. Patients with a specific type of breast cancer (HR-positive/HER2-positive) were given a shorter, 12-week round of targeted therapy combined with either mild chemotherapy or hormone therapy.

The results are amazing. After five years, the overall survival rate was nearly 100%. This means doctors can safely offer less intense treatments with fewer harsh side effects to women whose cancer is caught early. Only those who really need it will get the heavier chemotherapy, letting more patients keep their energy and quality of life.

For more details, see rssapp-clinicaladvisor-com at cancertherapyadvisor.com/news/de-escalated-neoadjuvant-regimen-hr-positive-her2-positive-early-breast-cancer/ (opens in new tab)